

# Cynomolgus EPHA10 Protein

Cat. No. EPH-CM110

## Description

<b>Source</b>	Recombinant Cynomolgus EPHA10 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Glu34-Ala565.
<b>Accession</b>	XP_045230088.1
<b>Molecular Weight</b>	The protein has a predicted MW of 58.56 kDa. Due to glycosylation, the protein migrates to 68-78 kDa based on Tris-Bis PAGE result.
<b>Endotoxin</b>	Less than 1EU per µg by the LAL method.
<b>Purity</b>	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

## Formulation and Storage


<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage</b>	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

## Background

EphA10 (erythropoietin-producing hepatocellular carcinoma receptor A10) is a catalytically defective receptor protein tyrosine kinase in the ephrin receptor family. EphA10 was elevated and higher in tumor tissues than in normal tissues in some cancer types, including pancreatic cancer. EphA10 silencing reduced the proliferation, migration, and adhesion of MIA PaCa-2 and AsPC-1 pancreatic cancer cells. EphA10 plays a pivotal role in the tumorigenesis of pancreatic epithelial cells and is a novel therapeutic target for pancreatic cancer.

## Assay Data


### Tris-Bis PAGE



Cynomolgus EPHA10 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

### SEC-HPLC

Assay Data



The purity of Cynomolgus EPHA10 is greater than 95% as determined by SEC-HPLC.